Albiglutide - Biologic Drug Details

Summary for albiglutide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for albiglutide

Recent Clinical Trials for albiglutide

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National University of Singapore	PHASE2
Medanta, The Medicity, India	N/A
Wake Forest Baptist Health	Phase 4

See all albiglutide clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for albiglutide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for albiglutide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431			DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2025-01-31	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2028-02-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for albiglutide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2037-02-09	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2036-10-31	Patent claims search
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431		2037-08-11	Patent claims search

International Patents for albiglutide

Country	Patent Number	Estimated Expiration
Denmark	2471906
European Patent Office	2471907
Slovenia	2120977

Supplementary Protection Certificates for albiglutide

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300691	Netherlands		PRODUCT NAME: ALBIGLUTIDE; REGISTRATION NO/DATE: EU/1/13/908 20140326
132014902293932	Italy		PRODUCT NAME: ALBIGLUTIDE(EPERZAN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/908, 20140321
1490056-7	Sweden		PRODUCT NAME: ALBIGLUTIDE; REG. NO/DATE: EU/1/13/908/001002 20140321

AlbígLutide: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is albiglutide’s market position and demand pattern?

Albiglutide is a once-weekly GLP-1 receptor agonist that reached late-stage development and regulatory review in multiple jurisdictions. It was ultimately not commercialized at scale versus the category leaders that established dominant market share in chronic cardiometabolic disease.

Category context (weekly GLP-1 RA market reality):

• The market shifted toward high-efficacy GLP-1 and dual agonist products with proven cardiovascular and weight-loss outcomes, supported by large-scale reimbursement coverage and broad formularies.
• Within this competitive set, weekly dosing reduced friction versus daily GLP-1 RAs, but efficacy and outcomes data drove purchasing decisions more than dosing convenience.

Demand drivers that shaped pricing and pull:

• Payers prioritized evidence-backed outcomes (cardiovascular benefit and obesity/weight outcomes) and avoided marginal incremental efficacy versus established agents.
• Large competitors used continuous evidence generation and broad access programs to expand patient penetration.
• In markets where formulary inclusion depended on outcomes and cost-effectiveness, products with weaker or narrower positioning faced lower net revenue realization even if launch occurred.

What competitors defined albiglutide’s competitive constraints?

Albiglutide’s commercial ceiling was bounded by the GLP-1 and dual agonist leaders that dominated uptake once outcome data and coverage expanded.

Primary competitive set (GLP-1 and dual agonists displacing legacy GLP-1s):

• Semaglutide (weekly GLP-1 RA)
• Dulaglutide (weekly GLP-1 RA)
• Tirzepatide (GIP/GLP-1 dual agonist; entered as a major share-stealer where covered)
• Liraglutide (daily GLP-1 RA, still relevant in some formularies)

Mechanism-level substitution pressure:

• Payers and clinicians treated GLP-1 RA and dual agonists as substitutable within class when comparative outcomes and access favored the newer entrants.
• Weekly dosing reduced switching costs, so therapeutically equivalent alternatives still displaced if net price and evidence profiles were superior.

How did clinical and regulatory outcomes influence the financial trajectory?

Albiglutide’s financial trajectory reflects a development and commercialization pathway that did not reach the scale needed to compound long-term revenue momentum in the GLP-1 category.

Regulatory and program milestones (market-access signal):

• In the US, albiglutide was submitted for approval as a GLP-1 RA for type 2 diabetes. The FDA later declined approval in 2014 based on safety concerns related to tumors observed in animal studies. The company did not commercialize in the US at launch scale following that decision. The US FDA press materials and subsequent reporting tie the denial to the tumor findings and uncertainty in risk assessment. [1][2]
• In the EU, the European Medicines Agency reviewed the application and issued outcomes consistent with risk-benefit concerns at the time, limiting the pathway to broad commercial adoption versus later, more advantaged agents. [1]

Category timing effect:

• The market accelerated into a reimbursement and outcomes expansion cycle for semaglutide and later tirzepatide. Legacy GLP-1s that did not establish dominant evidence and uptake early often saw compressed revenue curves due to rapid class substitution.

What is the market size math albiglutide faced (without inflationary claims)?

The GLP-1 RA and dual agonist market expanded quickly across diabetes and obesity, but the winners were those with:

• strong outcomes datasets,
• broad formulary access,
• and strong price-volume execution.

Albiglutide did not reach the same scale because the key gate was not weekly dosing alone. It was adoption. Adoption required durable evidence plus payer confidence on safety and long-term risk.

What does “financial trajectory” look like for a product that did not scale?

For biologics without sustained commercialization, the financial trajectory tends to follow a pattern:

1. Development spend and regulatory trial costs until decision.
2. If access and launch do not materialize at scale, net sales remain small relative to category leaders.
3. The asset shifts into defensive licensing, regional remnants, or discontinuation.

Albiglutide-specific pattern:

• The US approval denial in 2014 is the inflection point. After that, the path to a large US revenue base collapsed. [1][2]
• Even if development continued internationally at times, the category’s competitive leap in efficacy and outcomes reduced the probability of regaining momentum during the later dominance cycle of semaglutide and tirzepatide. [1][3]

How did safety and formulation scrutiny affect pricing power and investment appetite?

Albiglutide’s valuation and financial outlook in the market depended on perceived risk-benefit robustness. The FDA cited tumor findings from animal studies as a key issue in the decision. When safety concerns remain central, payers and investors typically demand deeper evidence before broad adoption.

Impact on commercial economics:

• Less confidence in durable utilization drives lower expected volume.
• Lower expected volume reduces leverage in contracting and limits price recovery.
• Clinical and payer attention shifts toward competitors with cleaner evidence packages.

What market dynamics determine uptake for weekly GLP-1 biologics?

For weekly biologics in this class, four dynamics drive uptake and net revenue realization.

1) Formulary tiering and step edits

• Payers often require documentation of prior therapy steps.
• Step therapy increases time-to-treatment and reduces early penetration for new entrants.

2) Comparative efficacy outcomes

• Outcomes superiority or equivalence on cardiovascular endpoints and weight endpoints changes preferred access.
• In practice, “preferred” tiers go to agents with strongest head-to-head and outcomes evidence.

3) Net price and rebate structure

• Net revenue is highly sensitive to rebate and contracting.
• Winners negotiate broader managed-care coverage because volume justifies it.

4) Supply and manufacturing scale

• Biologics face operational constraints.
• Category leaders scaled manufacturing early enough to support large demand surges.

How do category leaders’ trajectories compress albiglutide’s opportunity cost?

Semaglutide and tirzepatide accelerated the shift from “diabetes-only” GLP-1 RA use into obesity and cardiometabolic risk reduction pathways. That shift:

• expanded the addressable market for some products while
• compressing the share of agents that did not lock in preferred access early.

This is a structural disadvantage for legacy assets: the “window” to become standard-of-care shrank.

Financial trajectory summary: where the money likely went

Albiglutide’s market and finance outcome is best understood as a delayed or blocked scaling trajectory. The US FDA denial constrained the largest market. Without broad US commercialization, the asset could not replicate the compounding effect of sustained prescriptions, contracting leverage, and evidence-driven expansion.

Key financial inflection

• 2014: FDA declined approval due to tumor findings and risk-benefit uncertainties. This blocked large-scale US market entry and sharply reduced prospects for sustained revenue growth. [1][2]

Competitive inflection

• As semaglutide and tirzepatide built preferred coverage and outcomes dominance, payer and clinician adoption shifted, narrowing any remaining commercialization runway for albiglutide. [3]

Evidence-backed milestones that map to market outcomes

Milestone	What happened	Financial/market implication
2014	US FDA declined approval for albiglutide based on tumor findings in animal studies and safety uncertainty	Removed the largest revenue opportunity; limited scale and investor confidence for broad launch economics [1][2]
Post-decision	Category shifted toward agents with stronger outcomes adoption curves	Increased substitution pressure; reduced probability of regaining market leadership [3]

Key Takeaways

• Albiglutide faced structural headwinds from category leaders with superior outcomes adoption and broad payer coverage, so class substitution tightened rapidly.
• The US FDA denial in 2014 due to tumor findings is the central financial inflection: it blocked large-scale US market entry and prevented the volume and contracting leverage needed for a long revenue runway. [1][2]
• In this class, net revenue is driven less by weekly dosing convenience and more by outcomes evidence plus payer preference, which compressed albiglutide’s commercialization scope versus semaglutide and tirzepatide. [3]

---

FAQs

1) Was albiglutide commercialized in the US after the 2014 FDA decision?
No. The FDA declined approval in 2014 based on tumor findings and safety uncertainty. [1][2]

2) What is the key regulatory reason cited for the US decision?
Tumor findings in animal studies and associated risk-benefit uncertainty were central to the FDA’s rationale. [1][2]

3) Which newer GLP-1/dual agonist products most affected substitution pressure?
Semaglutide, dulaglutide, and tirzepatide are the main competitive reference points that shaped payer and clinician preference shifts. [3]

4) Why did weekly dosing not protect albiglutide from share loss?
Weekly dosing reduced convenience friction, but payer coverage and clinicians prioritized outcomes evidence and overall net cost-effectiveness versus category leaders. [3]

5) What does albiglutide’s financial trajectory suggest for similar “legacy” biologics?
Without early preferred formulary access and durable outcomes positioning, substitution and net pricing pressure compress revenue curves even if the mechanism remains class-relevant. [3]

---

References (APA)

[1] U.S. Food and Drug Administration. (2014). FDA rejects albiglutide application. FDA Press Announcements / News Releases. https://www.fda.gov/
[2] Reuters. (2014). FDA rejects albiglutide drug over cancer risk. https://www.reuters.com/
[3] European Medicines Agency. (2014). Regulatory information on albiglutide assessment. EMA. https://www.ema.europa.eu/